Quoc Le-Nguyen compensation by year
89bio Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $435,000 | $455,000 | $480,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $602,700 | $441,000 | $1,481,775 |
| Option awards | $234,080 | $1,368,516 | $1,490,249 |
| Non-equity incentive | $206,600 | $232,000 | $196,800 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $12,841 | $15,871 | $16,299 |
| Total | $1,491,221 | $2,512,387 | $3,665,123 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: 89bio, Inc. DEF 14A filed April 15, 2025, accession 0001193125-25-081504, and prior-year filings. Open the filing on EDGAR.
How this page was built: the 89bio, Inc. filed document, accession 0001193125-25-081504. Every figure is read from that document and cited to the page and table it appears in. Filed April 15, 2025.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 95,000 | $742,900 | — |
| RSU | 40,624 | $317,680 | — |
| PSU | 25,000 | $195,500 | — |
| RSU | 20,000 | $156,400 | — |
| RSU | 2,932 | $22,928 | — |
| Option | 195,000 | — | $9.98 |
| Option | 21,875 | — | $4.44 |
| Option | 4,219 | — | $23.01 |
| Option | 67,500 | — | $14.70 |
Per the Outstanding Equity Awards at Fiscal Year-End table in 89bio, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
19 Form 4 lines since the FY2024 proxy (filed April 15, 2025)current to 2026-11-10 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2025-10-30 | U | — | 13,694 | — | 0 |
| 2025-10-30 | Disposition to the issuer derivative | — | 70,000 | $0.00 | 0 |
| 2025-10-30 | Disposition to the issuer derivative | — | 195,000 | $0.00 | 0 |
| 2025-10-30 | Disposition to the issuer derivative | — | 17,500 | $0.00 | 0 |
| 2025-10-30 | Disposition to the issuer derivative | — | 120,000 | $0.00 | 0 |
| 2025-10-30 | Disposition to the issuer derivative | — | 67,500 | $0.00 | 0 |
| 2025-10-30 | U | — | 351,684 | — | 0 |
| 2025-10-30 | Grant or award | — | 50,000 | $0.00 | 351,684 |
The 8 most recent of 19 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments 89bio discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $360,000 | — | $21,010 | $381,010 |
| Change in control and involuntary termination | $480,000 | $1,704,846 | $28,014 | $2,404,860 |
Per the Potential Payments Upon Termination or Change in Control table in 89bio, Inc.'s FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
89bio’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Rohan Palekar | Chief Executive Officer and Director | $7,619,426 |
| Hank Mansbach | Chief Medical Officer | $3,689,407 |
| Quoc Le-Nguyen · this page | Chief Technical Operations Officer | $3,665,123 |
| Ryan Martins | Chief Financial Officer | $3,415,803 |
| Francis Sarena | Chief Operating Officer | $2,691,944 |
Quoc Le-Nguyen's compensation dossier, 89bio
You have read Quoc Le-Nguyen's totals and holdings. The dossier adds each equity grant 89bio disclosed for Quoc Le-Nguyen and 89bio's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full 89bio compensation record
free company briefThis page is one person within 89bio's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the 89bio proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order 89bio's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are 89bio's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order ETNB
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.